Form 4: Rapport Therapeutics Director Buys Shares
Insider Transaction (Form 4)
John Maraganore, a Director of Rapport Therapeutics, Inc., purchased 9,411 shares of common stock on October 22, 2026.
Summary
- Open-market purchase: acquired 8,239 Common Stock at $26.38 ($217,344) on October 22, 2026; holds 8,239 after (Indirect).
- Open-market purchase: acquired 1,172 Common Stock at $26.92 ($31,547) on October 22, 2026; holds 9,411 after (Indirect).
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a bullish signal: an insider made an open-market purchase of $248,891, committing personal capital to the stock.
Insider Transactions
John Maraganore — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-22 | Open-market purchase | Common Stock | 8,239 | $26 | $217.3K | 8,239 |
| 2026-10-22 | Open-market purchase | Common Stock | 1,172 | $27 | $31.5K | 9,411 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-22 | Open-market purchase (8,239 shares) |
| 2026-10-22 | Open-market purchase (1,172 shares) |
Keywords
insider transaction, Form 4, RAPP, Rapport Therapeutics, Inc., bullish, John Maraganore
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.